文献(501-606)

501. Smith CR, Leon MB, Mack MJ, et al. PARTNER Trial Investigators.Transcatheter versus surgical aortic-valve replacement in high-risk

patients. N Engl J Med 2011; 364: 2187-2198. PMID: 21639811

502. Mack MJ, Leon MB, Smith CR, et al. PARTNER 1 trial investigators. 5-year outcomes of transcatheter aortic valve replacement or

surgical aortic valve replacement for high surgical risk patients with aortic stenosis (PARTNER 1): a randomised controlled trial. Lancet

2015; 385: 2477-2484. PMID: 25788234

503. Vahanian A, Alfieri O, Al-Attar N, et al. Transcatheter valve implantation for patients with aortic stenosis: a position statement from the

European Association of Cardio-Thoracic Surgery (EACTS) and the European Society of Cardiology (ESC), in collaboration with the

European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2008; 29: 1463-1470. PMID: 18474941

504. Monin JL, Quéré JP, Monchi M, et al. Low-gradient aortic stenosis: operative risk stratification and predictors for long-term outcome: a

multicenter study using dobutamine stress hemodynamics. Circulation 2003; 108: 319-324. PMID: 12835219

505. Levy F, Laurent M, Monin JL, et al. Aortic valve replacement for low-flow/low-gradient aortic stenosis operative risk stratification and

long-term outcome: a European multicenter study. J Am Coll Cardiol 2008; 51: 1466-1472. PMID: 18402902

506. Pereira JJ, Lauer MS, Bashir M, et al. Survival after aortic valve replacement for severe aortic stenosis with low transvalvular gradients

and severe left ventricular dysfunction. J Am Coll Cardiol 2002; 39: 1356-1363. PMID: 11955855

507. Bauer F, Coutant V, Bernard M, et al. Patients with severe aortic stenosis and reduced ejection fraction: earlier recovery of left ventricular

systolic function after transcatheter aortic valve implantation compared with surgical valve replacement. Echocardiography 2013; 30:

865-870. PMID: 23489257

508. Pilgrim T, Wenaweser P, Meuli F, et al. Clinical outcome of high-risk patients with severe aortic stenosis and reduced left ventricular

ejection fraction undergoing medical treatment or TAVI. PLoS One 2011; 6: e27556. PMID: 22102909

509. Sannino A, Gargiulo G, Schiattarella GG, et al. Increased mortality after transcatheter aortic valve implantation (TAVI) in patients with

severe aortic stenosis and low ejection fraction: a meta-analysis of 6898 patients. Int J Cardiol 2014; 176: 32-39. PMID: 25042666

510. Eleid MF, Goel K, Murad MH, et al. Meta-Analysis of the Prognostic Impact of Stroke Volume, Gradient, and Ejection Fraction After

Transcatheter Aortic Valve Implantation. Am J Cardiol 2015; 116: 989- 994. PMID: 26195275

511. Stevenson LW, Pagani FD, Young JB, et al. INTERMACS profiles of advanced heart failure: the current picture. J Heart Lung Transplant

2009; 28: 535-541. PMID: 19481012

512. 日本胸部外科学会．J-MACS Statistical Report（2010年6月-2017年 7月）．http://www.jpats.org/uploads/uploads/files/J-MACS%

20Statistical%20Report%EF%BC%882010%E5%B9%B46%E6%9C%88-2017%E5%B9%B47%E6%9C%88%EF%BC%89.pdf

513. Kinugawa K. How to treat stage D heart failure? - When to implant left ventricular assist devices in the era of continuous flow pumps?

Circ J 2011; 75: 2038-2045. PMID: 21817817

514. Saito S, Matsumiya G, Sakaguchi T, et al. Fifteen-year experience with Toyobo paracorporeal left ventricular assist system. J Artif

Organs 2009; 12: 27-34. PMID: 19330502

515. Sasaoka T, Kato TS, Komamura K, et al. Improved long-term performance of pulsatile extracorporeal left ventricular assist device. J

Cardiol 2010; 56: 220-228. PMID: 20615667

516. Shiga T, Kinugawa K, Hatano M, et al. Age and preoperative total bilirubin level can stratify prognosis after extracorporeal pulsatile left

ventricular assist device implantation. Circ J 2011; 75: 121-128. PMID: 21116070

517. 日本循環器学会，日本心臓血管外科学会．循環器病の診断と治療に関するガイドライン2013．重症心不全に対する植込型補助人工

心臓治療ガイドライン．http://www.j-circ.or.jp/guideline/pdf/JCS2013_kyo_h.pdf

518. Nakatani T, Sase K, Oshiyama H, et al. J-MACS investigators. Japanese registry for Mechanically Assisted Circulatory Support: First

report. J Heart Lung Transplant 2017; 36: 1087-1096. PMID: 28942783

519. Kirklin JK, Pagani FD, Kormos RL, et al. Eighth annual INTERMACS report: Special focus on framing the impact of adverse events.

J Heart Lung Transplant 2017; 36: 1080-1086. PMID: 28942782

520. Rose EA, Gelijns AC, Moskowitz AJ, et al. Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart

Failure (REMATCH) Study Group. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med 2001; 345:

1435-1443. PMID: 11794191

521. Slaughter MS, Rogers JG, Milano CA, et al. HeartMate II Investigators. Advanced heart failure treated with continuous-flow left ventricular

assist device. N Engl J Med 2009; 361: 2241-2251. PMID:19920051

522. 日本循環器学会心臓移植委員会．心臓移植レシピエントの適応．http://www.j-circ.or.jp/hearttp/HTRecCriteria.html

523. Fukushima N, Ono M, Saiki Y, et al. Registry Report on Heart Transplantation in Japan (June 2016). Circ J 2017; 81: 298-303. PMID:

28070058

524. Stehlik J, Bavaria JE, Bax J, et al. Heart, lung, and vascular registries: Evolving goals, successful approaches, and ongoing innovation. J

Heart Lung Transplant 2016; 35: 1149-1157. PMID: 27772667

525. Jonkman NH, Westland H, Groenwold RH, et al. Do Self-Management Interventions Work in Patients With Heart Failure? An Individual

Patient Data Meta-Analysis. Circulation 2016; 133: 1189-1198.PMID: 26873943

526. Otsu H, Moriyama M. Effectiveness of an educational self-management program for outpatients with chronic heart failure. Jpn J Nurs

Sci 2011; 8: 140-152. PMID: 22117578

527. Kato N, Kinugawa K, Nakayama E, et al. Insufficient self-care is an independent risk factor for adverse clinical outcomes in Japanese

patients with heart failure. Int Heart J 2013; 54: 382-389. PMID: 24309448

528. Lainscak M, Blue L, Clark AL, et al. Self-care management of heart failure: practical recommendations from the Patient Care Committee

of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2011; 13: 115-126. PMID: 21148593

529. Kato N, Kinugawa K, Ito N, et al. Adherence to self-care behavior and factors related to this behavior among patients with heart failure

in Japan. Heart Lung 2009; 38: 398-409. PMID: 19755190

530. Matsuoka S, Tsuchihashi-Makaya M, Kayane T, et al. Health literacy is independently associated with self-care behavior in patients with

heart failure. Patient Educ Couns 2016; 99: 1026-1032. PMID:26830514

531. 日本心不全学会．心不全手帳．http://www.asas.or.jp/jhfs/topics/20130301.html

532. van der Wal MH, Jaarsma T. Adherence in heart failure in the elderly:problem and possible solutions. Int J Cardiol 2008; 125: 203-208.

PMID: 18031843

533. Kitzman DW. Outcomes in patients with heart failure with preserved ejection fraction: it is more than the heart. J Am Coll Cardiol 2012;

59: 1006-1007. PMID: 22402072

534. McAlister FA, Stewart S, Ferrua S, et al. Multidisciplinary strategies for the management of heart failure patients at high risk for

admission: a systematic review of randomized trials. J Am Coll Cardiol 2004; 44: 810-819. PMID: 15312864

535. Holland R, Battersby J, Harvey I, et al. Systematic review of multidisciplinary interventions in heart failure. Heart 2005; 91: 899-906.

PMID: 15958358

536. Fonarow GC. Heart failure disease management programs: not a class effect. Circulation 2004; 110: 3506-3508. PMID: 15583088

537. Powell LH, Calvin JE, Richardson D, et al. HART Investigators. Self-management counseling in patients with heart failure: the heart

failure adherence and retention randomized behavioral trial. JAMA 2010; 304: 1331-1338. PMID: 20858878

538. Galbreath AD, Krasuski RA, Smith B, et al. Long-term healthcare and cost outcomes of disease management in a large, randomized,

community-based population with heart failure. Circulation 2004;110: 3518-3526. PMID: 15531765

539. Riegel B, Moser DK, Anker SD, et al. State of the science: promoting self-care in persons with heart failure: a scientific statement from

the American Heart Association. Circulation 2009; 120: 1141-1163. PMID: 19720935

540. Ades PA, Keteyian SJ, Balady GJ, et al. Cardiac rehabilitation exercise and self-care for chronic heart failure. JACC Heart Fail 2013; 1:

540-547. PMID: 24622007

541. Davidson PM, Cockburn J, Newton PJ, et al. Can a heart failure-specific cardiac rehabilitation program decrease hospitalizations and

improve outcomes in high-risk patients? Eur J Cardiovasc Prev Rehabil 2010; 17: 393-402. PMID: 20498608

542. 後藤葉一．慢性心不全の疾病管理プログラムとしての外来心臓リハビリテーションをどう構築し運営するか？ Heart View 2014; 18:

520-527.

543. 後藤葉一．心不全に対する心臓リハビリテーションと運動療法．齋藤宗靖，後藤葉一，編．狭心症・心筋梗塞のリハビリテーショ

ン改訂第4版．南江堂 2009: 253-268.

544. World Health Organization. Organization. Global atlas of palliative care at the end of life.（ 2014年1月）

http://www.who.int/nmh/Global_Atlas_of_Palliative_Care.pdf

545. Allen LA, Yager JE, Funk MJ, et al. Discordance between patient- predicted and model-predicted life expectancy among ambulatory

patients with heart failure. JAMA 2008; 299: 2533-2542. PMID:18523222

546. Allen LA, Stevenson LW, Grady KL, et al. Decision making in advanced heart failure: a scientific statement from the American Heart

Association. Circulation 2012; 125: 1928-1952. PMID: 22392529

547. Detering KM, Hancock AD, Reade MC, et al. The impact of advance care planning on end of life care in elderly patients: randomised

controlled trial. BMJ 2010; 340: c1345. PMID: 20332506

548. 厚生労働省．人生の最終段階における医療の決定プロセスに関するガイドライン（2007年5月，改訂2015年3月）．

http://www.mhlw.go.jp/file/06-Seisakujouhou-10800000-Iseikyoku/0000078981.pdf

549. 日本心不全学会ガイドライン委員会．高齢心不全患者の治療に関するステートメント．2016．

http://www.asas.or.jp/jhfs/pdf/Statement_HeartFailurel.pdf

550. 日本集中治療学会．Do Not Attempt Resuscitation（DNAR）指示のあり方についての勧告．日集中医誌 2017; 24: 208-209.

http://www.jsicm.org/pdf/DNAR20170105.pdf

551. Qaseem A, Snow V, Shekelle P, et al. Evidence-based interventions to improve the palliative care of pain, dyspnea, and depression at

the end of life: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2008; 148: 141-146. PMID:

18195338

552. Lynn J. Perspectives on care at the close of life. Serving patients who may die soon and their families: the role of hospice and other

services. JAMA 2001; 285: 925-932. PMID: 11180736

553. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College

of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; 62: e147-e239. PMID:

23747642

554. 日本循環器学会．循環器病の診断と治療に関するガイドライン2011．循環器疾患における末期医療に関する提言．

http://www.j-circ.or.jp/guideline/pdf/JCS2010_nonogi_h.pdf

555. Gibbs JS, McCoy AS, Gibbs LM, et al. Living with and dying from heart failure: the role of palliative care. Heart 2002; 88 Suppl: ii36-

ii39. PMID: 12213799

556. Krumholz HM, Phillips RS, Hamel MB, et al. Resuscitation preferences among patients with severe congestive heart failure: results

from the SUPPORT project. Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments. Circulation 1998;

98: 648-655. PMID: 9715857

557. Levenson JW, McCarthy EP, Lynn J, et al. The last six months of life for patients with congestive heart failure. J Am Geriatr Soc 2000;

48: S101-S109. PMID: 10809463

558. Solano JP, Gomes B, Higginson IJ. A comparison of symptom prevalence in far advanced cancer, AIDS, heart disease, chronic

obstructive pulmonary disease and renal disease. J Pain Symptom Manage 2006; 31: 58-69. PMID: 16442483

559. Rutledge T, Reis VA, Linke SE, et al. Depression in heart failure a meta-analytic review of prevalence, intervention effects, and

associations with clinical outcomes. J Am Coll Cardiol 2006; 48: 1527-1537. PMID: 17045884

560. Johnson MJ, McDonagh TA, Harkness A, et al. Morphine for the relief of breathlessness in patients with chronic heart failure--a pilot

study. Eur J Heart Fail 2002; 4: 753-756. PMID: 12453546

561. Williams SG, Wright DJ, Marshall P, et al. Safety and potential benefits of low dose diamorphine during exercise in patients with chronic

heart failure. Heart 2003; 89: 1085-1086. PMID: 12923038

562. Evangelista LS, Sackett E, Dracup K. Pain and heart failure: unrecognized and untreated. Eur J Cardiovasc Nurs 2009; 8: 169-173.

PMID: 19150255

563. Schaefer KM, Shober Potylycki MJ. Fatigue associated with congestive heart failure: use of Levine’s Conservation Model. J Adv Nurs

1993; 18: 260-268. PMID: 8436716

564. Sherwood A, Blumenthal JA, Trivedi R, et al. Relationship of depression to death or hospitalization in patients with heart failure. Arch

Intern Med 2007; 167: 367-373. PMID: 17325298

565. Fosbøl EL, Gislason GH, Poulsen HE, et al. Prognosis in heart failure and the value of β-blockers are altered by the use of

antidepressants and depend on the type of antidepressants used. Circ Heart Fail 2009; 2: 582-590. PMID: 19919983

566. O’Connor CM, Jiang W, Kuchibhatla M, et al. SADHART-CHF Investigators. Safety and efficacy of sertraline for depression in patients

with heart failure: results of the SADHART-CHF (Sertraline Against Depression and Heart Disease in Chronic Heart Failure) trial. J Am

Coll Cardiol 2010; 56: 692-699. PMID: 20723799

567. May HT, Horne BD, Carlquist JF, et al. Depression after coronary artery disease is associated with heart failure. J Am Coll Cardiol 2009;

53: 1440-1447. PMID: 19371828

568. Angermann CE, Gelbrich G, Störk S, et al. MOOD-HF Study Investigators and Committee Members. Effect of Escitalopram on All-

Cause Mortality and Hospitalization in Patients With Heart Failure and Depression: The MOOD-HF Randomized Clinical Trial. JAMA

2016; 315: 2683-2693. PMID: 27367876

569. Milani RV, Lavie CJ. Impact of cardiac rehabilitation on depression and its associated mortality. Am J Med 2007; 120: 799-806. PMID:

17765050

570. Tu RH, Zeng ZY, Zhong GQ, et al. Effects of exercise training on depression in patients with heart failure: a systematic review and meta-

analysis of randomized controlled trials. Eur J Heart Fail 2014;16: 749-757. PMID: 24797230

571. Padeletti L, Arnar DO, Boncinelli L, et al. EHRA Expert Consensus Statement on the management of cardiovascular implantable

electronic devices in patients nearing end of life or requesting withdrawal of therapy. Europace 2010; 12: 1480-1489. PMID: 20675674

572. 補助人工心臓治療関連学会協議会．我が国における植込型補助人工心臓適応適正化の考え方：Destination Therapy について．

https://www.jacvas.com/view-dt

573. Swetz KM, Kamal AH, Matlock DD, et al. Preparedness planning before mechanical circulatory support: a “how-to” guide for palliative

medicine clinicians. J Pain Symptom Manage 2014; 47: 926-935.e6. PMID: 24094703

574. 日本救急医学会，日本集中治療医学会，日本循環器学会．救急・集中治療における終末期医療に関するガイドライン～ 3学会から

の提言～．http://www.jaam.jp/html/info/2014/pdf/info-20141104_02_01_02.pdf

575. Swedberg K, Komajda M, Böhm M, et al. SHIFT Investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised

placebo-controlled study. Lancet 2010; 376: 875-885. PMID:20801500

576. Böhm M, Swedberg K, Komajda M, et al. SHIFT Investigators. Heart rate as a risk factor in chronic heart failure (SHIFT): the association

between heart rate and outcomes in a randomised placebo-controlled trial. Lancet 2010; 376: 886-894. PMID: 20801495

577. McMurray JJ, Packer M, Desai AS, et al. PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus

enalapril in heart failure. N Engl J Med 2014; 371: 993-1004. PMID: 25176015

578. Yancy CW, Jessup M, Bozkurt B, et al. 2016 ACC/AHA/HFSA Fo cused Update on New Pharmacological Therapy for Heart Failure: An

Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/

American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation 2016;

134: e282-e293. PMID: 27208050

579. Tsutsui H, Momomura S, Saito Y, et al. Efficacy and safety of sacubitril/ valsartan (LCZ696) in Japanese patients with chronic heart

failure and reduced ejection fraction: Rationale for and design of the randomized, double-blind PARALLEL-HF study. J Cardiol 2017; 70:

225-231. PMID: 28024961

580. Solomon SD, Zile M, Pieske B, et al. Prospective comparison of ARNI with ARB on Management Of heart failUre with preserved

ejectioN fracTion (PARAMOUNT) Investigators. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved

ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet 2012; 380: 1387-1395. PMID: 22932717

581. Gheorghiade M, Marti CN, Sabbah HN, et al. Academic Research Team in Heart Failure (ART-HF). Soluble guanylate cyclase: a

potential therapeutic target for heart failure. Heart Fail Rev 2013; 18: 123- 134. PMID: 22622468

582. Greenberg B. Novel Therapies for Heart Failure　- Where Do They Stand? Circ J 2016; 80: 1882-1891. PMID: 27545139

583. Nossaman B, Pankey E, Kadowitz P. Stimulators and activators of soluble guanylate cyclase: review and potential therapeutic

indications. Crit Care Res Pract 2012; 2012: 290805. PMID: 22482042

584. Pieske B, Butler J, Filippatos G, et al. SOCRATES Investigators and Coordinators. Rationale and design of the SOluble guanylate

Cyclase stimulatoR in heArT failurE Studies (SOCRATES). Eur J Heart Fail 2014; 16: 1026-1038. PMID: 25056511

585. Gheorghiade M, Greene SJ, Butler J, et al. SOCRATES-REDUCED Investigators and Coordinators. Effect of Vericiguat, a Soluble

Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection

Fraction: The SOCRATES-REDUCED Randomized Trial. JAMA 2015; 314: 2251-2262. PMID: 26547357

586. A Study of Vericiguat in Participants With Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-001) (VICTORIA).

https://clinicaltrials.gov/show/NCT02861534

587. Malik FI, Hartman JJ, Elias KA, et al. Cardiac myosin activation: a potential therapeutic approach for systolic heart failure. Science

2011; 331: 1439-1443. PMID: 21415352

588. Cleland JG, Teerlink JR, Senior R, et al. The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic

heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial. Lancet 2011; 378: 676-683. PMID:21856481

589. Teerlink JR, Felker GM, McMurray JJV, et al. ATOMIC-AHF Investigators. Acute Treatment With Omecamtiv Mecarbil to Increase

Contractility in Acute Heart Failure: The ATOMIC-AHF Study. J Am Coll Cardiol 2016; 67: 1444-1455. PMID: 27012405

590. Teerlink JR, Felker GM, McMurray JJ, et al. COSMIC-HF Investigators. Chronic Oral Study of Myosin Activation to Increase Contractility

in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial. Lancet 2016; 388: 2895-2903.

PMID: 27914656

591. A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on

Mortality and Morbidity in Subjects With Chronic Heart Failure With Reduced Ejection Fraction (GALACTIC-HF).

https://clinicaltrials.gov/ct2/show/NCT02929329

592. Sawa Y, Miyagawa S. Present and future perspectives on cell sheetbased myocardial regeneration therapy. Biomed Res Int 2013; 2013:

583912. PMID: 24369013

593. Yoshikawa Y, Miyagawa S, Toda K, et al. Myocardial regenerative therapy using a scaffold-free skeletal-muscle-derived cell sheet in

patients with dilated cardiomyopathy even under a left ventricular assist device: a safety and feasibility study. Surg Today 2018; 48: 200-

210. PMID: 28821963

594. Miyagawa S, Domae K, Yoshikawa Y, et al. Phase I Clinical Trial of Autologous Stem Cell-Sheet Transplantation Therapy for Treating

Cardiomyopathy. J Am Heart Assoc 2017; 6: e003918. PMID:28381469

595. Sawa Y, Yoshikawa Y, Toda K, et al. Safety and Efficacy of Autologous Skeletal Myoblast Sheets (TCD-51073) for the Treatment of

Severe Chronic Heart Failure Due to Ischemic Heart Disease. Circ J 2015; 79: 991-999. PMID: 25912561

596. Tei C. Waon therapy: soothing warmth therapy. J Cardiol 2007; 49: 301-304. PMID: 17633566

597. Tei C, Horikiri Y, Park JC, et al. Acute hemodynamic improvement by thermal vasodilation in congestive heart failure. Circulation 1995;

91: 2582-2590. PMID: 7743620

598. Tei C, Tanaka N. Thermal vasodilation as a treatment of congestive heart failure: a novel approach. J Cardiol 1996; 27: 29-30. PMID:

8683432

599. Miyata M, Kihara T, Kubozono T, et al. Beneficial effects of Waon therapy on patients with chronic heart failure: results of a prospective

multicenter study. J Cardiol 2008; 52: 79-85. PMID: 18922381

600. Sobajima M, Nozawa T, Fukui Y, et al. Waon therapy improves quality of life as well as cardiac function and exercise capacity in

patients with chronic heart failure. Int Heart J 2015; 56: 203-208. PMID: 25740582

601. Kisanuki A, Daitoku S, Kihara T, et al. Thermal therapy improves left ventricular diastolic function in patients with congestive heart failure:

a tissue doppler echocardiographic study. J Cardiol 2007; 49: 187- 191. PMID: 17460879

602. Kihara T, Biro S, Imamura M, et al. Repeated sauna treatment improves vascular endothelial and cardiac function in patients with

chronic heart failure. J Am Coll Cardiol 2002; 39: 754-759. PMID:11869837

603. Kuwahata S, Miyata M, Fujita S, et al. Improvement of autonomic nervous activity by Waon therapy in patients with chronic heart failure.

J Cardiol 2011; 57: 100-106. PMID: 20884178

604. Kihara T, Biro S, Ikeda Y, et al. Effects of repeated sauna treatment on ventricular arrhythmias in patients with chronic heart failure. Circ

J 2004; 68: 1146-1151. PMID: 15564698

605. Kihara T, Miyata M, Fukudome T, et al. Waon therapy improves the prognosis of patients with chronic heart failure. J Cardiol 2009; 53:

214-218. PMID: 19304125

606. Tei C, Imamura T, Kinugawa K, et al. WAON-CHF Study Investigators. Waon Therapy for Managing Chronic Heart Failure　- Results

From a Multicenter Prospective Randomized WAON-CHF Study. Circ J 2016; 80: 827-834. PMID: 27001189